» Articles » PMID: 18980763

Clinical and Biochemical Presentations of Polycystic Ovary Syndrome Among Obese and Nonobese Women

Overview
Journal Fertil Steril
Date 2008 Nov 5
PMID 18980763
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To study the differences in clinical and biochemical characteristics between obese and nonobese women with polycystic ovary syndrome (PCOS).

Design: Retrospective study.

Setting: University teaching hospital.

Patient(s): Four hundred sixty-four Taiwan Chinese women, among whom 295 were diagnosed with PCOS and 169 were non-PCOS controls.

Main Outcome Measure(s): Body mass index, average menstrual interval, modified Ferriman-Gallwey score, acne, total T, and waist-to-hip ratio.

Result(s): Obese women with polycystic ovary morphology (PCOM) had a greater risk of developing of PCOS (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.5-10.4) than nonobese women with PCOM. Obese women with PCOM had a higher incidence oligomenorrhea (OR, 2.6; 95% CI, 1.6-4.1) and biochemical hyperandrogenemia (OR, 2.5; 95% CI, 1.6-4.0) than nonobese women with PCOM. Obese subjects with PCOS had a higher risk of developing oligomenorrhea (OR, 2.2; 95% CI, 1.3-3.7) and biochemical hyperandrogenemia (OR, 2.6; 95% CI, 1.6-4.2) than nonobese women with PCOS. Moreover, obese women with PCOS had significantly higher serum total T levels and more prolonged menstrual intervals than nonobese women with PCOS. Notably, the obese women with PCOS presented less acne than the nonobese subjects (OR, 0.5; 95% CI, 0.3-0.9).

Conclusion(s): Obese women with PCOS had more severe ovulatory dysfunction and higher serum total T levels than nonobese subjects. Moreover, obese women with PCOS had a significantly lower frequency of acne than nonobese subjects.

Citing Articles

Prospective associations of adolescent obesity phenotypes with self-reported polycystic ovary syndrome diagnosis in young adulthood.

Reich L, St Fleur R, Gjelsvik A, Field A, Ziobrowski H Hum Reprod. 2025; 40(3):545-552.

PMID: 39761509 PMC: 11879201. DOI: 10.1093/humrep/deae294.


Characterizing clinical and hormonal profiles of acne in north African women with polycystic ovary syndrome.

Ben Abdessalem F, Ach T, Ghariani Fetoui N, Mraihi E, Ben Abdelkarim A Arch Dermatol Res. 2024; 316(10):711.

PMID: 39460776 DOI: 10.1007/s00403-024-03466-3.


The impact of dietary interventions on polycystic ovary syndrome patients with a BMI ≥25 kg/m: A systematic review and meta-analysis of randomized controlled trials.

Yang J, Liang J, Xu J, Lin T, Ye Q, Lin Q Reprod Med Biol. 2024; 23(1):e12607.

PMID: 39351128 PMC: 11442045. DOI: 10.1002/rmb2.12607.


Association of Herbal Tea and Follicle-Stimulating Hormone, Anthropometric Parameters, and Fasting Blood Glucose Levels Among Polycystic Ovarian Syndrome Women: A Systematic Review and Meta-Analysis of Clinical Trials.

Abbasi E, Hajhashemy Z, Askari G, Saneei P Clin Nutr Res. 2024; 13(3):201-213.

PMID: 39165287 PMC: 11333146. DOI: 10.7762/cnr.2024.13.3.201.


Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators.

Wang L, Luo M, Yu X, Li R, Ye F, Xiong D J Ovarian Res. 2024; 17(1):78.

PMID: 38600539 PMC: 11005241. DOI: 10.1186/s13048-024-01405-4.